Literature DB >> 9423999

Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules.

M N Gaze1, C G Kelly, G R Kerr, A Cull, V J Cowie, A Gregor, G C Howard, A Rodger.   

Abstract

BACKGROUND: The optimum dose and fractionation schedule for the palliative irradiation of painful bone metastases is controversial.
PURPOSE: To compare the efficacy, side-effects and effect on quality of life of two commonly used radiotherapy schedules in the management of painful bone metastases.
MATERIALS AND METHODS: In a prospective trial, 280 patients were randomised to receive either a single 10 Gy treatment or a course of 22.5 Gy in five daily fractions for the relief of localised metastatic bone pain.
RESULTS: Response rates have been calculated from 240 assessable treated sites of pain. The overall response rates were 83.7% (single treatment) and 89.2% (five fractions). The complete response rates were 38.8% (single treatment) and 42.3% (five fractions). The median duration of pain control was 13.5 weeks (single treatment) and 14.0 weeks (five fractions). None of these differences was statistically significant. There were no differences between the groups in the effect of treatment on a variety of quality of life parameters.
CONCLUSIONS: It is concluded that a single 10 Gy treatment is as effective as a course of 22.5 Gy in five fractions in the management of painful bone metastases.

Entities:  

Mesh:

Year:  1997        PMID: 9423999     DOI: 10.1016/s0167-8140(97)00101-1

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  57 in total

Review 1.  WITHDRAWN: Radiotherapy for the palliation of painful bone metastases.

Authors:  Henry J McQuay; Sally L Collins; Dawn Carroll; R Andrew Moore; Sheena Derry
Journal:  Cochrane Database Syst Rev       Date:  2013-11-22

Review 2.  Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem.

Authors:  Matthew R Callstrom; J William Charboneau; Matthew P Goetz; Joseph Rubin; Thomas D Atwell; Michael A Farrell; Timothy J Welch; Timothy P Maus
Journal:  Skeletal Radiol       Date:  2005-10-05       Impact factor: 2.199

Review 3.  Malignant bone pain: pathophysiology and treatments.

Authors:  C Ripamonti; F Fulfaro
Journal:  Curr Rev Pain       Date:  2000

Review 4.  The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer.

Authors:  Jim N Rose; Juanita M Crook
Journal:  Ther Adv Urol       Date:  2015-06

5.  Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis.

Authors:  Tong Liu; Svetlana Romanova; Shuo Wang; Megan A Hyun; Chi Zhang; Samuel M Cohen; Rakesh K Singh; Tatiana K Bronich
Journal:  Mol Pharm       Date:  2019-06-14       Impact factor: 4.939

6.  A survey of patterns of practice on palliative radiation therapy for bone metastasis in Korea.

Authors:  Yoonsun Chung; Woong Sub Koom; Yong Chan Ahn; Hee-Chul Park; Hak Jae Kim; Sang Min Yoon; Sangjin Shin; Yoon Jae Lee
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-10       Impact factor: 4.553

7.  The spine instability neoplastic score (SINS) in the assessment of response to radiotherapy for bone metastases.

Authors:  E Gallizia; G Apicella; T Cena; M Di Genesio Pagliuca; L Deantonio; M Krengli
Journal:  Clin Transl Oncol       Date:  2017-06-16       Impact factor: 3.405

8.  Short Hypofractionated Radiation Therapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities.

Authors:  Stanislav Lazarev; Brian H Kushner; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-02       Impact factor: 7.038

9.  Long-term safety and efficacy of fractionated stereotactic body radiation therapy for spinal metastases.

Authors:  Frederick Mantel; Stefan Glatz; André Toussaint; Michael Flentje; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2014-06-27       Impact factor: 3.621

Review 10.  Radiotherapeutic approaches to metastatic disease.

Authors:  Edward Chow; Jackson Wu; Andrew Loblaw; Carlos A Perez
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.